Serum metabolic marker for tuberculosis drug resistance diagnosis and application thereof

A technique for metabolites, tuberculosis, applied in the field of molecular biomedicine

CN111077308AActive Publication Date: 2020-04-28佛山市第四人民医院 +1
3 Cites 10 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2020-04-28

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a serum metabolic marker for tuberculosis drug resistance diagnosis and application thereof. The serum metabolite is selected from at least one of 30 serum metabolite such as stearoyl glutamic acid; analysis is performed according to the serum metabolite of individuals with different tuberculosis drug resistance types; and a novel thought is provided for tuberculosis drug resistance diagnosis from the perspective of the serum metabolite.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of molecular biomedicine, in particular to serum metabolic markers for tuberculosis drug resistance diagnosis and applications thereof. Background technique

[0002] Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis (MTB) and mainly transmitted through the respiratory tract. In recent years, multidrug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (Extensively resistant tuberculosis, XDR-TB) phenomenon has become increasingly serious. According to the 2018 WHO report, among the 6.7 million new tuberculosis patients worldwide in 2017, about 6.8% were MDR-TB, of which India, China and Russia accounted for 24%, 13% and 10% respectively. MDR-TB is the resistance of Mycobacterium tuberculosis to at least two first-line anti-tuberculosis drugs, isoniazid (INH) and rifampicin (RIF). of deaths could be prevented through early diagnosis and treatment, suggesting th...

Examples

Embodiment 1

[0040] The inventors based on the determination of a total of 30 cases of tuberculosis drug sensitivity (drug sensitivity, DS), 8 cases of monoresistance isoniazid (monoresistance isoniazide, MR-INH), 2 cases of monoresistance rifampin (monoresistance rifampin, MR-RFP) ), 14 cases of multidrug resistance (MDR), 24 cases of multidrug resistance (polyresistance, PR) serum samples of metabolites were analyzed, and the metabolic markers were identified.

[0041] The relative abundance of differential metabolites in drug-resistant and drug-sensitive groups is shown in Table 1.

[0042] Table 1 Relative abundance of differential metabolites in TB drug resistance and DS groups

[0043]

[0044] By comparing the abundance of metabolites in the serum samples of tuberculosis drug-resistant individuals and tuberculosis drug-susceptible individuals, stearoyl glutamic acid, 5-Pentacosyl-1,3-benzonediol, 25-hydroxycholesterol, dihydroxy-26,27-dimethyl-20,21-didehydro-23-oxavitamin D3, 2...